Tilray Brands Prepares for U.S. Medical Cannabis Expansion After Federal Rescheduling
In December 2025, Tilray Brands, Inc. (Nasdaq: TLSY; TSX: TLSY) announced that its medical division, Tilray Medical, is moving forward with a strategic framework to expand its U.S. medical cannabis operations following the federal rescheduling of cannabis. The company highlighted the formation of Tilray Medical USA, Inc., a dedicated entity designed to navigate the evolving regulatory landscape while maintaining the high standards of quality and compliance that have defined its international business.
Leadership Perspective on Policy Change
Irwin D. Simon, Chairman and Chief Executive Officer of Tilray Brands, described the rescheduling decision as a “constructive and necessary evolution” of U.S. federal policy. He noted that the move aligns regulation with a growing body of scientific evidence supporting the safety and therapeutic potential of cannabis, and emphasized that it creates a more credible foundation for research, clinical development, and patient‑focused oversight.
Simon added that Tilray has spent years building the infrastructure, scientific expertise, and regulatory know‑how required to operate responsibly in federally legal medical cannabis markets. He said the company is prepared to engage thoughtfully and in full compliance, leveraging its experience from more than 20 international markets.
Global Experience and Current Footprint
Tilray Medical currently offers more than 200 registered medical cannabis products across international markets and has served over 500,000 registered patients worldwide. The company has participated in more than 15 medical cannabis studies and clinical trials in partnership with leading hospitals and physicians, investigating cannabinoids for conditions such as pediatric epilepsy, cancer‑induced nausea, PTSD, chronic pain, anxiety, essential tremors, alcohol use disorder, fibromyalgia, glioblastoma, and driving performance.
This global track record provides Tilray with mature compliance systems, scientific data, and governance practices that it intends to adapt to the U.S. context as federal policy evolves.
Planned U.S. Strategy
Tilray Medical USA plans to introduce medical‑grade cannabis products in targeted therapeutic formats, drawing on real‑world data and physician insights gathered from its international operations. The company aims to expand collaborations with healthcare operators and medical professionals, ensuring all partnerships align with emerging federal and state medical guidelines.
By focusing on standardization, evidence‑based therapies, and patient safety, Tilray hopes to support the development of an integrated state‑federal medical cannabis framework within the U.S. healthcare system.
Looking Ahead
The rescheduling of cannabis represents a potential catalyst for expanded access to medical research, improved product standardization, and broader patient access to cannabis‑based therapies. Tilray’s proactive approach—grounded in its proven global expertise—positions the company to play a leading role in shaping the next phase of medical cannabis in the United States.
For more details on the announcement, see the original press release Here.
